Publication Name	World Journal of Gastroenterology
Manuscript ID	31467
Country	Mexico

Received	2016-11-18 09:19
Peer-Review Started	2016-11-18 17:41
First Decision by Editorial Office Director
Return for Revision	2017-03-07 19:46
Revised	2017-03-22 09:33
Publication Fee Transferred
Second Decision by Editor	2017-05-27 01:05
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2017-06-01 08:48
Articles in Press	2017-06-01 08:48
Edit the Manuscript by Language Editor
Typeset the Manuscript	2017-06-21 09:11
Publish the Manuscript Online	2017-06-26 10:23

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Pharmacology & Pharmacy
Manuscript Type	Basic Study
Article Title	Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways
Manuscript Source	Invited Manuscript
All Author List	Erika Hernández-Aquino, Natanael Zarco, Sael Casas-Grajales, Erika Ramos-Tovar, Rosa E Flores-Beltrán, Jonathan Arauz, Mineko Shibayama, Liliana Favari, Víctor Tsutsumi, José Segovia and Pablo Muriel
Funding Agency and Grant Number	Funding Agency Grant Number National Council of Science and Technology (Conacyt) of Mexico 253037 National Council of Science and Technology (Conacyt) of Mexico 239516 Fellowship from Conacyt 358378
Corresponding Author	Pablo Muriel, PhD, Laboratory of Experimental Hepatology, Department of Pharmacology, CINVESTAV-IPN, Av. Instituto Politécnico Nacional 2508, Apartado Postal 14–740, 07000, Mexico City, Mexico. pmuriel@cinvestav.mx
Key Words	Fibrosis; Transforming growth factor-β; Naringenin; pSmad3; Smad3; JNK; Nuclear factor kappa; Carbon tetrachloride
Core Tip	To study the effect of naringenin (NAR) on carbon tetrachloride (CCl4)-induced chronic liver fibrosis, male Wistar rats were administered 400 mg of CCl4/kg body weight and 100 mg of NAR/kg body weight for 8 wk. NAR prevented necrosis, cholestasis, oxidative stress, collagen accumulation and the increase in MMP activity caused by CCl4 administration. NAR completely prevented the increase in TGF-β, α-SMA, CTGF, Col-1, MMP-13, NF-κB, IL-1 and IL-10 protein levels caused by CCl4 administration and pSmad3 and pJNK activation. In conclusion, NAR prevents CCl4 induced liver fibrosis due to its antioxidant capacity and by inhibiting the TGF-β-Smad3, JNK-Smad3 and NF-κB pathways.
Publish Date	2017-06-26 10:23
Citation	Hernández-Aquino E, Zarco N, Casas-Grajales S, Ramos-Tovar E, Flores-Beltrán RE, Arauz J, Shibayama M, Favari L, Tsutsumi V, Segovia J, Muriel P. Naringenin prevents experimental liver fibrosis by blocking TGFβ-Smad3 and JNK-Smad3 pathways. World J Gastroenterol 2017; 23(24): 4354-4368
URL	http://www.wjgnet.com/1007-9327/full/v23/i24/4354.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i24.4354

Full Article (PDF)	WJG-23-4354.pdf
Full Article (Word)	WJG-23-4354.doc